Cell Type–Specific Roles of CD38 in the Interactions of Isoniazid with NAD⁺ in the Liver

Junjie Zhu, Jie Lu, Hung-Chun Tung, Ke Liu, Jiahua Li, Denis M. Grant, Wen Xie, and Xiaochao Ma

Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania (J.Z., J.L., H.-C.T., K.L., J.L., W.X., X.M.) and Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (D.M.G.)

Received June 9, 2020; accepted September 24, 2020

ABSTRACT

NAD⁺ is a critical molecule that is involved in multiple cellular functions. CD38 is a multifunctional enzyme with NAD⁺ nucleosidase activity. Our previous work revealed the CD38-dependent interactions of isoniazid (INH), an antituberculosis drug, with NAD⁺ to form INH-NAD adduct. In the current work, our metabolomic analysis discovered a novel NAD⁺ adduct with acetylisoniazid (AcINH), a primary INH metabolite mediated by N-acetyltransferase (NAT), and we named it AcINH-NAD. Using Nat1/2(−/−) and Cd38(−/−) mice, we determined that AcINH-NAD formation is dependent on both NAT and CD38. Because NAT is expressed in hepatocytes (HP), whereas CD38 is expressed in Kupffer cells (KC) and hepatic stellate cells (HSC), we explored cell type–specific roles of CD38 in the formation of AcINH-NAD as well as INH-NAD. We found that both INH-NAD and AcINH-NAD were produced in the incubation of INH or AcINH with KC and HSC but not in HP. These data suggest that hepatic nonparenchymal cells, such as KC and HSC, are the major cell types responsible for the CD38-dependent interactions of INH with NAD⁺ in the liver.

SIGNIFICANCE STATEMENT

The current study identified AcINH-NAD as a novel metabolite of INH in the liver. Our work also revealed the essential roles of nonparenchymal cells, including Kupffer cells and hepatic stellate cells, in the CD38-dependent interactions of NAD⁺ with INH, leading to the formation of both INH-NAD and AcINH-NAD in the liver. These data can be used to guide the future studies on the mechanisms of INH and NAD⁺ interactions and their contributions to INH-induced liver injury.

Introduction

Tuberculosis is a major public health problem worldwide and has caused around 1.3 million deaths in 2017 (World Health Organization, 2018). Isoniazid (INH, isonicotinohydrazide), discovered in 1952, remains the first-line drug for tuberculosis prophylaxis and therapy. However, INH treatment is accompanied with potential adverse events, including hepatotoxicity. Approximately 10%–20% of INH-treated patients have a transient elevation of plasma aminotransferases, and about 1% of patients encounter liver injury and even fulminant liver failure (Scharer and Smith, 1969; Garibaldi et al., 1972; Nolan et al., 1999). Although the underlying mechanisms of INH-induced liver injury have not yet been defined, INH metabolism is thought to be related to INH hepatotoxicity (Nelson et al., 1976; Timbrell et al., 1980; Sarich et al., 1996; Boelsterli and Lee, 2014; Wang et al., 2016).

This work was supported in part by National Institutes of Health National Institute of Allergy and Infectious Diseases [Grant R01AI131983 to X.M.] and the National Center for Complementary and Integrative Health [Grant R21AT011088 to X.M.].

https://doi.org/10.1124/dmd.120.000139.

ABBREVIATIONS: AcHz, acetylhydrazine; AcINH, acetylisoniazid; AcONH₂, ammonium acetate; CLEC4F, C-type lectin domain family 4 member F; HP, hepatocyte; HSC, hepatic stellate cell; Hz, hydrazine; INH, isoniazid; KC, Kupffer cell; MS/MS, tandem mass spectrometry; m/z, mass-to-charge ratio; NAT, N-acetyltransferase; NPC, nonparenchymal cell; OPLS-DA, orthogonal partial least-squares discriminant analysis; qPCR, quantitative real-time polymerase chain reaction; α-SMA, α-smooth muscle actin; UPLC-QTOFMS, ultra-performance liquid chromatography and quadrupole time-of-flight mass spectrometry; WT, wild-type.
liver (Li et al., 2016). Additionally, INH causes protoporphyrin IX accumulation in the liver through the induction of δ-aminolevulinate synthase 1 and downregulation of ferrochelatase (Sachar et al., 2016). Furthermore, INH can react with NAD+ to form INH-NAD adduct (1-(2R,3R,4S,5R)-5-(((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)(phosphoryl)oxy)(hydroxy)(phosphoryl)oxy)(hydroxy)phosphoryl)-3,4-dihydroxytetrahydrofuran-2-yl)-4-(hydrazinecarbonyl)pyridin-1-ium) as catalyzed by CD38, a multifunctional enzyme with NAD+ nucleosidase activity (Zatman et al., 1954; Li et al., 2016; Chini et al., 2018).

NAD+ is involved in multiple cellular functions, including redox reactions, DNA repair, cell cycle regulation, and calcium signaling (Malavasi et al., 2008; Lee, 2012; Stein and Imai, 2012; Fouquerel and Sobol, 2014; Imai and Guarente, 2014; Chini et al., 2018). Interactions between NAD+ and INH may disrupt NAD+ homeostasis and in turn lead to cellular dysfunctions. Hence, a comprehensive study on the interactions between INH and NAD+ is needed. Using a metabolomic approach, the current work revealed a novel NAD+ adduct with INH metabolite AcINH in the liver—namely, AcINH-NAD (4-(2-acetylhydrazinecarbonyl)-1-(((2R,3S,4R,5R)-5-(((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)(phosphoryl)oxy)(hydroxy)(phosphoryl)oxy)(hydroxy)phosphoryl)-3,4-dihydroxytetrahydrofuran-2-yl)pyridin-1-ium). Additionally, genetically engineered mouse models, including Nat1/2(-/-) and Cd38(-/-) mice, were used to determine the roles of NAT and CD38 in the formation of INH-NAD and AcINH-NAD, respectively. Because NAT is expressed in hepatocytes (HP), whereas CD38 is expressed in Kupffer cells (KC) and hepatic stellate cells (HSC) (Oesch and Steinberg, 1987; March et al.,

<table>
<thead>
<tr>
<th>Gene</th>
<th>Orientation</th>
<th>Sequence (5’–3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albumin</td>
<td>Forward</td>
<td>TGCCTTTTCACGGGTTGTT</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>TTACCTCGCACTAAATTTGGCA</td>
</tr>
<tr>
<td>F4/80</td>
<td>Forward</td>
<td>GCTGTGAGATTGTGGAAAGCA</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>ATGGCCAAGGCGACAGACAT</td>
</tr>
<tr>
<td>Clec4f</td>
<td>Forward</td>
<td>GAGGGCGAGTGCAAGAG</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>TGGAGGCGCCACAAANAAAGA</td>
</tr>
<tr>
<td>Desmin</td>
<td>Forward</td>
<td>GACACCTACCGGGAAGCTACT</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>GCAGAAGAGGTGTGGAAGGAA</td>
</tr>
<tr>
<td>α-Sma</td>
<td>Forward</td>
<td>AACAAGGAAATACGACGAAG</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>CAGGAAATGGTGGGAAGGA</td>
</tr>
<tr>
<td>Cyp2e1</td>
<td>Forward</td>
<td>CAAGTCTTTACAAAGGAGAA</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>CCACAGTGGCCTCTCTGA</td>
</tr>
<tr>
<td>Nat1</td>
<td>Forward</td>
<td>GATTACAAGCAGATTTTGGACACCATAGTA</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>CACCTTGACTAGAGGTGGGAAC</td>
</tr>
<tr>
<td>Cd38</td>
<td>Forward</td>
<td>TTGCAAGGTTCTTGGAAAC</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>CGCTCCTCATTACATCTCA</td>
</tr>
<tr>
<td>Cyclophilin</td>
<td>Forward</td>
<td>TGGAGGACACCAAGACAGA</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>GCCCGTAGGCTCTGCTG</td>
</tr>
</tbody>
</table>

**Fig. 1.** Identification of AcINH-NAD by a metabolomic analysis of mouse liver. WT mice were treated with vehicle (control) or INH (73 mg/kg, by mouth) for 1 hour. Liver samples were collected and analyzed by UPLC-QTOFMS. (A) Separation of liver samples from control and INH groups in an OPLS-DA score plot. (B) A loading S-plot generated by OPLS-DA analysis. (C) MS/MS spectrum of AcINH-NAD. (D) MS/MS spectrum of INH-NAD. The structures of AcINH-NAD and INH-NAD with MS/MS fragmentation patterns are inlaid in the spectra.
2007), we further explored the cell type–specific roles of CD38 in the formation of INH-NAD and AcINH-NAD by using primary mouse liver cells, including HP, KC, and HSC.

Materials and Methods

Chemicals and Reagents. INH, NAD+, CD38 from porcine brain, and ammonium acetate (AcONH₄) were purchased from Sigma-Aldrich (St. Louis, MO). AcINH was purchased from Toronto Research Chemical (Toronto, ON, Canada). Nicotinamide-2,4,5,6-d₄ was purchased from CDN Isotopes (Pointe-Claire, QC, Canada). All solvents for ultra-performance liquid chromatography and quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS) analysis were of the highest grade commercially available.

Animals and Treatments. Nat1/2(−/−) mice were generated and provided by Dr. Denis M. Grant’s laboratory (Sugamori et al., 2003). Cd38(−/−) mice were purchased from the Jackson Laboratory. Wild-type (WT), Nat1/2(−/−), and Cd38(−/−) mice (male, 8–12 weeks old, C57BL/6 background) were treated with vehicle (water) or INH (73 mg/kg, by mouth). At 1 hour later, mouse livers were harvested and stored at −80°C until further analysis. For the dose-dependent effects of INH on the formation of INH-NAD and AcINH-NAD in the liver, WT mice were treated with INH (73 or 200 mg/kg, by mouth), and the livers were collected 15 minutes postdose. For the pharmacokinetic analysis of INH-NAD and AcINH-NAD, WT mice were treated with INH (73 mg/kg, by mouth), and mouse sera and livers were harvested at 0, 0.25, 0.5, 1, 2, 4, 8, and 24 hours postdose. All animal studies were approved by the Institutional Animal Care and Use Committee of the University of Pittsburgh.

Sample Preparation for Metabolite Analysis. The extraction of metabolites from mouse livers was performed according to a previous report, with a minor modification (Zhu et al., 2018). In brief, 100 mg of liver sample was homogenized in 600 μl of water containing nicotinamide-2,4,5,6-d₄ as an internal standard, and then 1.2 ml of acetonitrile/methanol (1:1, v/v) was added to the resulting suspension. The mixture was then mixed on a vortex mixer and centrifuged at 15,000 rpm for 10 minutes. A 2-μl aliquot of the supernatant was injected into the UPLC-QTOFMS system for metabolite analysis.

Formation of AcINH-NAD in the Incubation with AcINH and CD38. Incubations were carried out in 1× PBS (pH = 7.4) containing porcine CD38 (1.0 mg/ml), 2 mM NAD+, and 200 μM AcINH in a final volume of 100 μl. The groups in the absence of CD38 or NAD+ or AcINH were used as controls. After 2 hours of incubation at 37°C, the reactions were terminated by adding 100 μl of water containing nicotinamide-2,4,5,6-d₄, as an internal standard, and then 1.2 ml of acetonitrile/methanol (1:1, v/v) was added to the resulting suspension. The mixture was then mixed on a vortex mixer and centrifuged at 15,000 rpm for 10 minutes. A 2-μl aliquot of the supernatant was injected into the UPLC-QTOFMS system for metabolite analysis.

Isolation and Culture of Primary Mouse Liver Cells. Livers from WT mice (male, 8–12 weeks old) were perfused with calcium and magnesium-free Hanks’ balanced salt solution (Hyclone, Logan, UT) and digested with Liberase TM (Roche, Mannheim, Germany). The resulting cell suspension was filtered through a 100-μm cell strainer and further centrifuged at 500 rpm for 3 minutes at 4°C. The supernatants were rich in nonparenchymal cells (NPC). The pellet containing...
HP was washed twice with cold Williams’ E medium (Sigma-Aldrich), and then HP were seeded onto six-well plates precoated with type 1 collagen (Discovery Labware, Bedford, MA) in Williams’ E medium containing 5% FBS. After the attachment of HP, the culture medium was changed to HepatoZYMES-FHM (Thermo Fisher Scientific, Carlsbad, CA), a hepatocyte maintenance medium. HSC were isolated from the NPC fraction by Nycodenz (Accurate Chemical, Westbury, NY) density gradient centrifugation as previously described (Mederacke et al., 2015). Isolated HSC were seeded onto six-well plates with Dulbecco’s modified Eagle’s medium (Sigma-Aldrich) containing 10% FBS, and morphology was checked under light microscopy. KC were isolated from the NPC fraction using Percoll (Sigma-Aldrich) density gradient centrifugation and purified by selective adherence following prior reports (Smedsnud and Pertof, 1985; Cabral et al., 2018). KC were cultured with RPMI 1640 medium (HyClone) containing 10% FBS. All the primary cells were incubated at 37°C under a 5% CO₂ humidified atmosphere. HP, KC, and HSC were verified by quantitative real-time polymerase chain reaction (qPCR) analysis of cell type–specific genes (Table 1).

**qPCR Analysis.** Total RNA was extracted from cells using TRIzol reagent, and cDNA was prepared using random hexamer primers and Moloney Murine Leukemia Virus Reverse Transcriptase (Thermo Fisher Scientific). qPCR was performed using the QuantStudio 6 Flex System (Applied Biosystems, Foster City, CA). The qPCR primers of target genes are listed in Table 1. The expression level of each target gene was normalized against cyclophilin.

**Formation of INH-NAD and AcINH-NAD in Primary Mouse Liver Cells.** HP, KC, and HSC were incubated with 1 mM NAD⁺ and different concentrations of INH (100, 500, and 1000 μM) or AcINH (50, 250, and 500 μM) in corresponding culture medium. At 4 hours later, 100 μl of medium was collected and mixed with 100 μl of methanol/acetonitrile (1:1, v/v) to precipitate proteins. The postcentrifugation (15,000 rpm for 10 minutes) supernatants were injected into UPLC-QTOFMS for the analyses of INH-NAD and AcINH-NAD. Meanwhile, cells were harvested after washing twice with 1× PBS (pH 7.4). The suspension mixture containing cells was sonicated and centrifuged to give supernatants, which were dried and reconstituted in 100 μl of water/acetonitrile (1:1, v/v) for UPLC-QTOFMS analysis. Cellular proteins concentrations were measured by Pierce BCA protein assay kit (Thermo Fisher Scientific). The abundance of INH-NAD and AcINH-NAD was normalized to cellular protein concentrations.

**UPLC-QTOFMS Analysis.** The analyses were performed on an Acquity UPLC Ethylene Bridged Hybrid Amide column (2.1 × 150 mm, 1.7 μm) coupled with a SYNAPT G2-S mass spectrometer (Waters Corporation, Milford, MA). The column temperature was set at 50°C. The mobile phases for the separation were A (10 mM AcONH₄, 5% acetonitrile in water) and B (10 mM AcONH₄, 5% water in acetonitrile). The elution gradient was set as follows: 0.0–1.0 minute, 15% A; 1.0–7.0 minutes, 15%–60% A; 7.0–10.0 minutes, 60% A; 10.0–10.5 minutes, 60%–1% A; 10.5–13.0 minutes, 1% A; 13.0–13.5 minutes, 1%–15% A; 13.5–15.0 minutes, 15% A. The QTOFMS system was operated in a positive high-resolution mode with electrospray ionization. The mass parameters were set as previously reported (Liu et al., 2017; Zhu et al., 2018). Collision energy ramping from 10 to 45 eV was used for structural elucidation of INH metabolites.

**Data Analysis.** Multivariate data analyses of the liver samples were performed similarly as previously reported (Liu et al., 2017; Zhu et al., 2018). In brief, the mass data acquired by MassLynx 4.1 were exported into SIMCA-P software (version 13; Umetrics, Kinnelon, NJ), and orthogonal partial least-squares discriminant analysis (OPLS-DA) was further conducted to maximize the class discrimination. An S-plot was generated and used for screening of novel metabolites. Structures of metabolites were elucidated based on accurate mass measurement (mass errors less than 10 ppm) and tandem mass spectrometry (MS/MS) fragmentation analysis.

**Statistical Analysis.** Data are expressed as means or means ± S.D. Statistical analyses were performed with a two-tailed Student’s t test (for two groups) or one-way ANOVA (for multiple groups), and a P value <0.05 was considered as statistically significant.

**Results**

**Identification of AcINH-NAD in Mouse Liver.** A metabolomic study was conducted for the livers from WT mice treated with vehicle (control) or INH. The control and INH groups were well separated to the corresponding clusters by OPLS-DA (Fig. 1A). A novel metabolite, named AcINH-NAD herein, ranked as one of the top ions in the S-plot (Fig. 1B). AcINH-NAD was eluted at 5.30 minutes. AcINH-NAD has a protonated molecular ion [M + H] at mass-to-charge ratio (m/z) 721.1428, and the MS/MS fragmentation ions were at m/z 542, 524, 428, 348, 232, 180, and 136 (Fig. 1C). The fragmentation ion at m/z = 180 indicates the structure of AcINH. By further comparing with the MS/MS of INH-NAD (Fig. 1D), we elucidated the structure of AcINH-NAD, in which the nicotinamide group of NAD⁺ was replaced by AcINH (Fig. 1D).

**Dose- and Time-Dependent Formation of INH-NAD and AcINH-NAD in Mouse Liver.** The formation of INH-NAD and AcINH-NAD is dose-dependent. INH-NAD and AcINH-NAD are undetectable in the vehicle group. In the group with a high dose of INH (200 mg/kg), the abundance of INH-NAD and AcINH-NAD is significantly higher than that in the lower-dose group (73 mg/kg) (Fig. 2, A and B). We also investigated the pharmacokinetics of INH-NAD and AcINH-NAD in the liver. After INH administration, both INH-NAD and AcINH-NAD were quickly formed in the liver, reached the highest levels at 15 minutes, and then decreased to undetectable levels after 4 hours (Fig. 2, C and D), which is consistent with the pharmacokinetics of hepatic INH and AcINH (Wang et al., 2017). INH-NAD and AcINH-NAD could not be detected in mouse sera after INH.
treatment. AcINH-NAD seems less abundant than INH-NAD by comparing their peak areas (Fig. 2, C and D), although the differences of their ionization efficiencies cannot be ruled out.

The Role of NAT in the Production of INH-NAD and AcINH-NAD. Nat1/2(−/−) mice were used to determine the role of NAT in the formation of INH-NAD and AcINH-NAD. Compared with WT mice, hepatic AcINH-NAD was decreased by 75% in Nat1/2(−/−) mice treated with INH (Fig. 3A), suggesting that NAT plays an important role in AcINH-NAD formation. On the other hand, the abundance of INH-NAD was statistically significantly increased in the liver of Nat1/2(−/−) mice treated with INH (Fig. 3B), which is because deficiency of NAT slows down INH acetylation, leading to INH accumulation in the liver and therefore increasing the interactions between INH and NAD⁺. The increase of INH-NAD in the liver of Nat1/2(−/−) mice is consistent with our previous finding that NAT deficiency increases the interactions of INH with endobiotics in the liver (Wang et al., 2017).

The Role of CD38 in the Production of INH-NAD and AcINH-NAD. To determine the role of CD38 in AcINH-NAD formation, AcINH was incubated with CD38. We found that AcINH-NAD formation was dependent on three components—AcINH, NAD⁺, and CD38 (Fig. 4A)—which is similar to the CD38-dependent formation of INH-NAD (Li et al., 2016). These data suggest that CD38 hydrolyzes the nicotinamide group from NAD⁺ and substitutes it with AcINH, leading to the production of AcINH-NAD (Fig. 4B). To further verify the role of CD38 in the formation of AcINH-NAD as well as INH-NAD, Cd38(−/−) mice were used. In line with a previous report (Aksoy et al., 2006), NAD⁺ levels were significantly increased in the liver of Cd38(−/−) mice treated with INH (73 mg/kg, by mouth, n = 4). The abundance of INH-NAD and AcINH-NAD in WT mice was set as 100%, respectively. Data are expressed as means ± S.D. N.D., not detected. ****P < 0.0001.

Cell Type-Specific Role of CD38 in the Formation of INH-NAD and AcINH-NAD. We next explored the contribution of HP, KC, and HSC to the formation of INH-NAD and AcINH-NAD. These cells were isolated from mouse liver and characterized by their specific markers, including F4/80, C-type lectin domain family 4 member F (Clec4f), Desmin, and α-smooth muscle actin (α-Sma) (Fig. 5, A and B). Based upon the relative expression of these cell type-specific markers, we estimated that the purity of HP is 100%, and the purity of KC and HSC is 90%. We also analyzed INH-metabolizing enzymes in these cells, including Cyp2e1 and Nat1. As expected, Cyp2e1 and Nat1 are highly expressed in HP but very low in KC and HSC (Fig. 5, C and D). Conversely, Cd38 is highly expressed in KC and HSC but very low in HP (Fig. 5E), which is consistent with a previous report (March et al., 2007). In agreement with CD38 expression in liver cells (Fig. 5E), both INH-NAD and AcINH-NAD were produced predominantly in the culture medium of KC and HSC incubated with INH (Fig. 6, A and B) or AcINH (Fig. 6, C and D), but to a much lesser degree in that of HP. These data indicate that KC and HSC are the major cell types responsible for the CD38-mediated formation of INH-NAD and AcINH-NAD in

Fig. 4. Role of Cd38 in the formation of INH-NAD and AcINH-NAD. (A) Formation of AcINH-NAD in the incubation with AcINH, NAD⁺, and Cd38 (n = 3). Cd38 (1.0 mg/ml), 2 mM NAD⁺, and 200 μM AcINH were incubated in a final volume of 100 μl of 1× PBS for 2 hours. (B) Scheme of AcINH-NAD formation. (C) Hepatic NAD⁺ levels in WT and Cd38(−/−) mice without INH treatment. The abundance of NAD⁺ in WT mice was set as 1. (D and E) Formation of INH-NAD (D) and AcINH-NAD (E) in the liver of WT and Cd38(−/−) mice treated with INH (73 mg/kg, by mouth, n = 4). The abundance of INH-NAD and AcINH-NAD in WT mice was set as 100%, respectively. Data are expressed as means ± S.D. N.D., not detected. ****P < 0.0001.
the liver. In addition, intracellular INH-NAD and AcINH-NAD were undetectable, which is attributed to the primary location of CD38 in cell membrane (Malavasi et al., 2008).

Discussion

The current work provided novel insights into the interactions between INH and NAD⁺ in the liver. Using a metabolomic approach, we identified AcINH-NAD as a novel metabolite of INH. Our further studies revealed that AcINH-NAD formation is dependent on both NAT and CD38. Moreover, we determined KC and HSC as the major hepatic cell types contributing to the CD38-dependent formation of AcINH-NAD as well as INH-NAD (Fig. 6E).

The distribution of NAT and CD38 in different cell types determines the production process of INH-NAD and AcINH-NAD in the liver. The liver consists of parenchymal HP and NPC, which account for 60%–70% and 30%–40% of total liver cells, respectively (Alpini et al., 1994; Si-Tayeb et al., 2010). NAT is mainly expressed in HP, whereas CD38 is predominantly expressed in NPC, including KC and HSC (Oesch and Steinberg, 1987; March et al., 2007). KC and HSC locate in the perisinusoidal space (or space of Disse), where INH can be metabolized by CD38 to form INH-NAD. When INH enters HP, it can be metabolized by NAT to produce AcINH, the major metabolite of INH. Next, AcINH is diffused from HP into the perisinusoidal space and thereby exposed to CD38 on KC and HSC, leading to the formation of AcINH-NAD (Fig. 6E).

This is the first study that reveals the contribution of hepatic NPC to INH metabolism. NPC, such as KC and HSC, are capable of metabolizing endobiotics and xenobiotics (Oesch and Steinberg, 1987). KC have been disclosed to uptake and metabolize environmental pollutants (Zhong et al., 1994). HSC have high expression of CYP1B1, which is responsible for the metabolism of retinoids (Piscaglia et al., 1999; Choudhary et al., 2004; Friedman, 2008). Nevertheless, the current work uncovered the sequential metabolism of INH in HP and NPC, leading to the formation of AcINH-NAD. This process provides an example for the joint activities of multiple cell types to form one metabolite in drug metabolism.

CD38 has NAD⁺ nucleosidase activity that hydrolyzes NAD⁺ to nicotinamide and adenosine diphosphate ribose (Kontani et al., 1993; Aksoy et al., 2006; Chini et al., 2018). In addition, CD38 mediates the replacement action of the nicotinamide group in NAD⁺ by a series of pyridine analogs, including INH (Zatman et al., 1954; Anderson et al., 1959; Li et al., 2016). AcINH has a similar chemical structure as nicotinamide; hence, it is feasible that CD38 catalyzes the interactions of AcINH and NAD⁺, leading to AcINH-NAD formation. Extrapolated from the current work, other pyridine-containing drugs may also interact with NAD⁺ via CD38 to form drug-NAD adducts. NAD⁺ analogs with minor changes in NAD⁺ structure would likely disrupt biologic functions of NAD⁺. Ara-NAD and Carba-NAD, two NAD⁺ analogs with modifications of the ribose group in NAD⁺ structure, are potent CD38 inhibitors (Chini et al., 2018). In addition, introduction of an amino group to the purine moiety of NAD⁺ leads to a more efficient substrate of poly(ADP-ribosyl) transferase than NAD⁺ (Oei et al., 1996). Because of the structural similarities of INH-NAD and AcINH-NAD with NAD⁺, further studies are needed to determine whether INH-NAD and AcINH-NAD disrupt NAD⁺-dependent pathways in the liver.

Cell-cell communications between HP and NPC have been implicated in many physiologic and pathophysiologic processes, including cell growth, migration, and differentiation (Bhatia et al., 1999). KC are the liver resident macrophages, and they are associated with a series of acute and chronic liver diseases through the release of inflammatory mediators and/or reactive oxygen species (Dixon et al., 2013). KC activation also

Fig. 5. Expression of INH-metabolizing enzymes in primary mouse liver cells. (A and B) Characterization of HP, KC, and HSC by qPCR: Albumin for HP; F4/80 and Clec4f for KC; and Desmin and α-Sma for HSC. (C–E) mRNA expression of Cyp2e1 (C), Nat1 (D), and Cd38 (E) in HP, KC, and HSC. The data in HP were set as 1. All data are expressed as means ± S.D. (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 vs. HP.
contributes to drug-induced liver injury (Roberts et al., 2007). HSC are liver fibrogenic cells, which are also involved in hepatic inflammation via the production of cytokines and chemokines (Friedman, 2008). Therefore, further studies are warranted to investigate the effects of INH-NAD and AcINH-NAD on KC and HSC functions and their impact on cell-cell communications between HP and NPC.

In summary, the current work identified AcINH-NAD as a novel metabolite of INH in the liver. Our work also revealed the essential roles of KC and HSC in the CD38-dependent interactions of NAD⁺ with INH in the liver. The data from this work can be used to guide the future studies on the mechanisms of INH and NAD⁺ interactions and their contributions to INH-induced liver injury.

**Authorship Contributions**

*Participated in research design:* Zhu, Ma.

*Conducted experiments:* Zhu, Lu, Tung, Liu, Li.


